A Risk-Benefit Assessment of Alendronate in the Treatment of Involutional Osteoporosis

ISSN： 0114-5916

Source： Drug Safety, Vol.19, Iss.2, 1998-08, pp. : 141-154

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of Treatment with Calcitriol Combined with Low-Dosage Alendronate in Involutional Osteoporosis

By Nuti R. Martini G. Giovani S. Valenti R.

Clinical Drug Investigation, Vol. 19, Iss. 1, 2000-01 ,pp. : 55-61

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Sildenafil in the Treatment of Erectile Dysfunction

By Vitezic D.

Drug Safety, Vol. 24, Iss. 4, 2001-01 ,pp. : 255-265

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Injections of Hyaluronan and its Derivatives in the Treatment of Osteoarthritis of the Knee

By Adams M.E.

Drug Safety, Vol. 23, Iss. 2, 2000-08 ,pp. : 115-130

Adis International

Access to resources Recommend Favorite

Interferon- Treatment of Patients with Hepatitis C: The Role of a Comprehensive Risk-Benefit Assessment

By Muhamad Aly Rifai Loftis Jennifer M. Hauser Peter

CNS Drugs, Vol. 19, Iss. 8, 2005-01 ,pp. : 719-721

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Risperidone for the Treatment of Behavioural and Psychological Symptoms in Dementia

By Zaudig M.

Drug Safety, Vol. 23, Iss. 3, 2000-09 ,pp. : 183-195

Adis International

Access to resources Recommend Favorite